Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KURA ONCOLOGY, INC.

(KURA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wedbush Cuts Kura Oncology's Price Target to $40 From $53 After KO-539 Partial Clinical Hold; Outperform Rating Kept

11/24/2021 | 10:26am EST


ę MT Newswires 2021
All news about KURA ONCOLOGY, INC.
01/21Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Ac..
AQ
01/20FDA Lifts Hold Kura Oncology's KOMET-001 Phase 1b Study of KO-539 Patients With Relapse..
MT
01/20KURA ONCOLOGY, INC. : Other Events (form 8-K)
AQ
01/20Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 ináAc..
AQ
01/20Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539..
CI
2021Kura Oncology Initiates Dosing in Phase 1/2 Clinical Trial of Head, Neck Cancer Combo T..
MT
2021Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combinat..
GL
2021Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Co..
CI
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura ..
PR
2021Kura Oncology Reports 56% Overall Response Rate in T-Cell Lymphoma Drug Study
MT
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -134 M - -
Net cash 2021 497 M - -
P/E ratio 2021 -5,81x
Yield 2021 -
Capitalization 784 M 784 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 116
Free-Float 94,3%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 11,78 $
Average target price 37,57 $
Spread / Average Target 219%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President & Chief Executive Officer
Marc Edward Grasso Chief Financial & Business Officer
Mollie Leoni Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.-15.86%784
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-1.60%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624